Cathie Wood Invests $15.3 Million in Ionis Pharmaceuticals Amid Stock Decline

Cathie Wood's ARK Genomic Revolution ETF has invested $15.3 million in Ionis Pharmaceuticals (IONS) following a stock decline due to a late-stage trial failure for one of its drugs, eplontersen. Despite the setback, Wood appears confident in IONS' long-term potential.

By James Halley, The Motley Fool Sat, July 18, 2026 at 5:20 PM GMT+3 5 min read · Yahoo Finance · July 18, 2026, 14:20 UTC

Cathie Wood Invests $15.3 Million in Ionis Pharmaceuticals Amid Stock Decline

Tickers: $ARKG $AZN $IONS

Topics: Biotech ETF Investing Ionis Pharmaceuticals Pharmaceuticals

Read the full article at Yahoo Finance

More World news

The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC